MTTI Announces Favorable Three-Year Follow-Up for EBTATE in Neuroendocrine Tumors

Molecular Targeting Technologies, Inc. (MTTI) announced favorable findings of a 3-year follow-up of EBTATE (3 cycles, 3.7 GBq/cycle) against metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Results from this study were published in Theranostics.¹

EBTATE is the first patented long-acting peptide targeting radiotherapeutic drug. It selectively targets somatostatin receptor 2 (SSTR2) on GEP-NETs, which are then killed by the radionuclide payload. The Evans blue moiety in EBTATE binds to serum albumin, extending in vivo circulatory half-life and residence time, enabling effective but lower radioactivity and fewer dosing cycles vs. the current standard of care (SOC). These findings confirm the safety and efficacy of the previous EBTATE results in 62 NET patients.

Professor Zhaohui Zhu, MD, principal investigator, said “Low occurrence of short and long-term toxicity proved EBTATE is safe (N=29). None of the patients developed leukemia or bone marrow disease during the 3-year follow-up. We observed low incidence of grade 3 hematoxicity (3.4% vs 15% of reported SOC) and no nephrotoxicity of any grade in long-term safety evaluation. Using EBTATE at lower radioactivity (37%) was as effective as SOC in disease control and achieved higher objective response based on RECIST criteria.”

Chris Pak, President & CEO of MTTI commented: “It is rewarding to see how EBTATE helped these patients. We look forward to the same benefits from EBTATE trials in small cell lung cancer, nasopharyngeal cancers, Hürthle cell thyroid and others.”

Molecular Targeting Technologies, Inc. (MTTI). MTTI is a privately held, venture-backed, clinical-stage biotech company developing next-generation targeted radiotherapeutics for rare cancers with high unmet needs. MTTI is committed to building value by translating innovative radiopharmaceutical assets to improve human health and reduce healthcare costs. MTTI is orchestrating multiple clinical trials. For more information: www.evathera.com.

¹Jiang Y, Liu Q, Wang G, et al. Safety and efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTA-EB-TATE (EBTATE) in patients with metastatic neuroendocrine tumors. Theranostics. 2022;12(15):6437-6445.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230619893678/en/